Clinical trial
Irinotecan and Gemcitabine in Treating Patients With Refractory Advanced Solid…
NCT00054288 · Roswell Park Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00054288 |
|---|---|
| Title | Irinotecan and Gemcitabine in Treating Patients With Refractory Advanced Solid Tumors |
| Official title | Escalating Irinotecan (CPT-11) Administered 24 Hours Prior To Gemcitabine In Patients With Refractory Solid Tumors |
| Lead sponsor | Roswell Park Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride, irinotecan hydrochloride |
| Start date | Aug 1, 2001 |
| Primary completion | May 1, 2003 |
| Completion | Jun 1, 2009 |
| First posted | Feb 6, 2003 |
| Last update posted | Jan 13, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: